30
Participants
Start Date
January 28, 2020
Primary Completion Date
February 9, 2023
Study Completion Date
February 9, 2023
SQZ-PBMC-HPV
antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
Atezolizumab
programmed cell death ligand 1 (PD-L1) blocking antibody
Ipilimumab
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
Nivolumab
programmed cell death 1 (PD-1) blocking antibody
Vanderbilt University Medical Center, Nashville
University Hospital Cologne, Clinic I for Internal Medicine, Cologne
The Masonic Cancer Center University of Minnesota, Minneapolis
University of Kansas Cancer Center, Kansas City
OU Health Stephenson Cancer Center, Oklahoma City
University of Colorado Anschutz Cancer Pavillion, Aurora
HonorHealth, Scottsdale
Cedars-Sinai Medical Center, Los Angeles
Providence Cancer Institute, Portland
Massachusetts General Hospital, Boston
University of Nebraska Medical Center, Omaha
Princess Margaret Cancer Centre, Toronto
SQZ Biotechnologies
INDUSTRY